Mochi Health review 2026: the marketplace play, examined

Mochi Health is the consumer brand of Mochi Health Corp., a cash-pay telehealth platform launched to serve compounded-GLP-1 weight-loss patients. The platform itself does not deliver clinical care. As Mochi's own footer states, "all professional medical services are provided by licensed physicians and clinicians affiliated with independently owned and operated professional practices. Mochi Health Corp. provides administrative and technology services to affiliated medical practices it supports, and does not provide any professional medical services itself." This admin-platform / affiliated-medical-practice split is standard for cash-pay telehealth. Federal court records identify the affiliated entities as Mochi Medical CA PC (the California professional corporation) and Mochi Medical PA (the Texas-style professional association) — both named as co-defendants in the Eli Lilly federal lawsuit (see section 06).

The product model is what makes Mochi distinctive in our set. Where most competitors connect a patient to whichever clinician is available in their state and to a single in-house or contracted pharmacy, Mochi presents a marketplace: after the eligibility quiz, the patient picks the healthcare provider whose schedule and style fit them, and then picks the pharmacy they want their prescription routed to. The dietitian layer — included with every membership — is also marketed as included rather than à la carte.

The headline category is compounded GLP-1 weight loss. The home page mentions skincare, hair growth, mental health, and pediatrics as additional services, but the detail level on those is thin compared to the GLP-1 focus, and they're not the product the company is selling against. Two compounded medications are explicitly named in pricing: compounded injectable semaglutide and compounded injectable tirzepatide.

Mochi's pricing structure is two-component: a Mochi Health membership (the platform layer with physician access, dietitian, customer support, and education) plus a separate per-month medication cost. The home page shows the structure plainly enough, but the all-in monthly number isn't foregrounded — patients see the medication add-on price ($99 for semaglutide, $199 for tirzepatide) and the membership ($79/mo, currently $39 promotional first month) as separate line items.

Prices current as of 10 June 2026, taken from Mochi Health's home page. The home page shows month/3-month/6-month/12-month plan selectors but does not publish the multi-month membership math on the static surface — the specific commitment pricing is exposed inside the onboarding flow rather than on the marketing page. We re-verify pricing periodically.

Mochi Health Membership

Mochi's home page promo: "$39 promotional rate available for new subscribers only. After the first month, monthly membership fee increases to $79/month. Promotional pricing not available in all states."

Medication add-on (on top of membership)

Effective all-in monthly cost. A new patient on compounded semaglutide pays $39 (promo membership) + $99 (medication) = $138 first month, then $79 + $99 = $178/mo thereafter. For tirzepatide: $238 first month, then $278/mo thereafter. These are competitive entry points for compounded GLP-1, but the recurring $79 membership is the kind of charge a patient might mentally treat as a one-time signup fee rather than an indefinite monthly add-on. Worth knowing.

Multi-month membership commitments. The home page offers 1-month, 3-month, 6-month, and 12-month membership selectors, but the specific multi-month pricing isn't published on the static surface — it appears inside the onboarding flow. The pattern at most cash-pay-telehealth providers is that longer commitments carry "paid in full" discounts at the cost of mid-term cancellation friction. We have not entered Mochi's onboarding to extract those specifics; we'll re-check when we re-pull pricing.

Insurance / FSA / HSA / BNPL. Mochi does not advertise FSA/HSA acceptance on the home page, does not list Klarna/Affirm/Afterpay options, and does not accept insurance. Cash-pay only.

Mochi describes the funnel as four steps, lighter on quoted timelines than most competitors.

Eligibility quiz. A short questionnaire establishes whether the patient is a candidate for the platform's care.

Pick a provider. The marketplace step: choose a healthcare provider whose schedule and style fit you, from a pool the platform makes visible after the quiz. This is the distinctive bit — most competitors don't expose provider choice at this stage.

Pick a pharmacy. The patient selects from "pharmacies you trust." The marketplace claim is that Mochi works with multiple compounding pharmacies and lets the patient pick which one ships their prescription. The specific in-network pharmacies are not publicly disclosed by name on the homepage.

Ongoing support. Unlimited access to dietitians/nutritionists for coaching and support.

Shipping. Mochi's FAQ states: "Prescriptions can take up to 10 days for delivery. Most people receive them in less time." A separate FAQ acknowledges that GLP-1 medications "may remain stable at room temperature for up to 28 days" and that "each of our partner pharmacies performs their own stability testing" — reassurance copy for the thawed-ice-pack complaints common in compounded-GLP-1 logistics.

Mochi's weight-loss outcomes ride on the underlying molecules. The honest question is what compounded semaglutide and tirzepatide can do, and what's realistic.

For semaglutide, the STEP 1 trial found adults with overweight or obesity lost on average 14.9% of body weight at 68 weeks on once-weekly 2.4 mg semaglutide, versus about 2.4% on placebo, both arms paired with lifestyle support. For tirzepatide, the SURMOUNT-1 trial showed larger average losses — into the 20%+ range at the higher doses over 72 weeks. Weight regain after stopping is well-documented; the STEP 1 extension trial found participants regained roughly two-thirds of the weight they had lost within a year of discontinuing semaglutide.

Two honest caveats. First, every one of those trials studied branded, FDA-approved semaglutide or tirzepatide at defined doses. Mochi dispenses compounded versions, which are not the studied products and are not FDA-reviewed for safety or efficacy. The expectation is that the same active molecule behaves similarly, but that's an inference, not trial data. Second, FDA FAERS-based reviews of compounded GLP-1 prescriptions (2018–2024) have documented elevated rates of nausea, abdominal pain, gallbladder complications, and hospitalizations relative to branded GLP-1s, alongside potency errors in some compounded sublingual products. This is a category-level signal, not a Mochi-specific one, but it belongs in any reader's mental model.

Mochi's home page foregrounds several quantitative outcome claims: "10% weight loss is achieved in six months for over half of our members," "36 pounds is the average weight loss for our members in their first year," "5/6 of our members stay at least a second month," and "patients achieve an average weight loss of 16% in their first year." These are presented prominently — separate hero panels — but none of them are footnoted to a study, audit, or external source. They are uncited company-marketing claims. Under our editorial standards, claims of this kind are recorded as what the company says but not propagated as evidence of outcomes. The branded-drug pivotal trials above are the actual evidence base for what these medications can do.

GLP-1 therapy is a well-characterized drug class, and the side-effect profile is consistent across providers. The most common effects are gastrointestinal: nausea, reduced appetite, constipation or diarrhea, and mild digestive discomfort, typically most noticeable when starting or stepping up a dose and often easing with time and dose adjustment. Less common but more serious risks documented for the class include pancreatitis and gallbladder problems. Branded GLP-1s carry a boxed warning based on rodent studies of thyroid C-cell tumors, and are not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN2. Pregnancy is a contraindication. Mochi's FAQ lists the common milder effects ("GI issues like nausea, constipation, diarrhea, and heartburn") but doesn't foreground the more serious contraindications on the home page — a prescribing provider is supposed to screen for them at intake, and patients should raise their history directly.

One Mochi-specific item worth flagging: the platform offers a pediatric line (a dedicated /pediatrics page exists on the site). Compounded GLP-1 prescribing to pediatric populations is an elevated regulatory and editorial sensitivity. The pediatric page was not snapshotted in this review and the protocol detail isn't on the home page. Anyone considering Mochi for pediatric weight management should ask specifically about BMI thresholds, age cutoffs, parental consent flow, and the prescribing provider's pediatric credentials.

None of this is unique to Mochi at the GLP-1 level — it's the category's standard risk picture — but a thorough review should state it.

The single most important context for any compounded-GLP-1 provider in 2026 is the regulatory squeeze. The FDA removed tirzepatide from its shortage list in December 2024 and semaglutide in February 2025; the 503A grace period ended 22 April 2025 and the 503B grace period 22 May 2025. On 30 April 2026 the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List permanently, with public comment open until 29 June 2026. The practical effect is that mass-compounding of these drugs no longer rests on a shortage justification; what remains is narrower, patient-specific compounding. Mochi's two named medications — compounded semaglutide and compounded tirzepatide — are inside the proposed exclusion scope.

Mochi does not foreground 503A versus 503B language on the home page. The marketplace pharmacy model — patients "pick a pharmacy you trust" from a panel of partners — assumes the patient can make an informed choice between options. But the in-network pharmacies are not publicly named, their 503A/503B classifications are not posted, and the patient has no way to compare them at the marketing-page level. Whether that opacity changes inside the onboarding flow is unclear to us and worth verifying with the company directly.

Three concurrent legal proceedings. Mochi has unusually broad active litigation exposure for a single provider. (1) Eli Lilly federal lawsuit (filed 23 April 2025). Per NPR reporting, Lilly's complaint against Mochi specifically alleges that Mochi "switched its patients to compounded tirzepatide with different additives, like niacinamide" and that the company changed patient doses "at least five times in just eight months" to keep selling compounded tirzepatide. Co-defendants include Henry Meds, Willow Health, Fella Health, and Delilah. Per Law360 (22 April 2026), U.S. District Judge Jacqueline Scott Corley denied Mochi's bid to dismiss the case in April 2026, keeping it mostly intact. Mochi Medical CA PC and Mochi Medical PA are named as co-defendants. (2) Novo Nordisk lawsuit. Mochi also faces a parallel lawsuit from Novo Nordisk over compounded semaglutide (per Reddit r/JoinMochiHealth discussion, ~10 months prior); the specific docket and current status are open items. (3) California class action — worker misclassification. Per Lexology (24 February 2026), a class action lawsuit was filed in the Northern District of California against Mochi Health on 11 February 2026 alleging the company misclassified its telehealth providers (1099 contractors vs W-2 employees). This case is separate from the manufacturer lawsuits.

Mochi's public statement on the litigation (April 23, 2025) says the company is "continuing to provide care" during the proceedings.

Because availability of compounded tirzepatide and semaglutide specifically is the most regulation-sensitive data point here — and is the subject of active manufacturer litigation — we'll recheck it after the 29 June 2026 FDA comment deadline and as the federal lawsuits progress.

Mochi's home-page pricing block lists two medications by name (compounded semaglutide, compounded tirzepatide) plus a vague "treatments across skincare, hair growth, and more" line. The marketing meta-description claims "120+ conditions," but the public detail surface for non-GLP-1 categories is thin compared to the GLP-1 focus.

A dedicated /pediatrics page exists, with a /pharmacy page and /medications page for additional detail. None of these were captured at the level required to map a full menu in this review. Mochi reads as a GLP-1-first platform that gestures at broader breadth, rather than a true multi-category provider in the TeleZenMD or Hims sense.

The one feature Mochi emphasizes that most cash-pay-only competitors don't is registered dietitian coaching included with every membership. The home page lists "Nutrition coaching sessions" as included. The marketplace concept extends to the dietitian step in the sense that the patient gets a credentialed nutrition professional rather than just a chatbot or a generic content library.

Whether the dietitian layer translates to better outcomes than a medication-only competitor is an open empirical question. There is solid evidence in the broader obesity-medicine literature that medication plus structured behavioral or nutritional support outperforms medication alone over the long term. Mochi's own outcome statistics (uncited, see §04) cannot answer this question; an independent randomized comparison would be required.

The category is real and the inclusion is a meaningful structural difference. Whether it earns its weight at $79/mo is a personal value call.

Reading the conflicting third-party signals. Mochi presents an unusually split external picture. Trustpilot shows a 4-star rating across 16,207 reviews — one of the largest sample sizes in the compounded-DTC category. The Better Business Bureau, by contrast, lists Mochi with a 1.32-out-of-5 customer review rating (per Forbes' April 2026 review), with documented complaint history primarily related to refund disputes and lack of treatment response. These instruments measure different things: Trustpilot captures self-selected user satisfaction at scale and is shaped by the company's solicitation patterns, while BBB captures complaints that escalate beyond company-internal resolution. Both are real signals. Mochi's active litigation profile — three concurrent legal proceedings, see section 06 — is a third independent signal that warrants its own weight.

Pros.

Marketplace model is real. Patients do get provider choice and pharmacy choice at the structural level — fewer competitors offer either, much less both. Stated value is meaningful even if the in-network pharmacy list isn't public.

Registered dietitian included with every membership. Less common in compounded-GLP-1 cash-pay than the medication-only model.

Large Trustpilot footprint. Trustpilot shows 16,207 reviews at 4 stars — one of the largest independent-review samples in the compounded-DTC category.

Press footprint is broad — Mochi's home page cites mentions in Washington Post, USA Today, WSJ, Bloomberg, CNBC, Forbes, NPR, Wired, STAT, and others. Each specific story would need separate verification before propagating its content, but the breadth of trade-press attention is real.

Featured marketplace physicians have verifiable credentials. Two of the four physicians foregrounded on Mochi's home page were cross-checked against the public NPI Registry — one with Family Medicine plus Obesity Medicine taxonomy (TX-licensed), one with Internal Medicine plus FACP credential (RI-licensed). Both individually registered and actively licensed with the credentials Mochi describes.

Cons and trade-offs.

BBB customer review rating is 1.32 out of 5 stars. Per Forbes Health's April 2026 Mochi Health review, 28 April 2026"), Mochi's BBB profile shows a 1.32-star customer review rating with complaints "primarily related to refund disputes and lack of treatment response." A Reddit r/MochiHealthSnark thread (1 year prior) reported that Mochi had "stopped responding to BBB complaints" — current responsiveness to BBB complaints is an open item.

Outcome statistics are uncited. "10% in six months for over half of members," "36 lbs avg in year one," "16% in year one" — all marketing without a footnote to any study, audit, or external source. Treat as company-stated, not as evidence.

Three concurrent legal proceedings. Mochi is defendant in: (1) Eli Lilly federal lawsuit on compounded tirzepatide (filed April 2025; dismissal denied April 2026 by Judge Corley, keeping case "mostly intact" per Law360); (2) Novo Nordisk lawsuit on compounded semaglutide (parallel manufacturer suit); (3) California class action on worker misclassification (filed February 2026). The combined legal exposure is the broadest in our set and is itself a material consideration for new signups. See section 06 for details and sources.

In-network pharmacies are not publicly named. "Pick a pharmacy you trust" assumes the patient has trust signals to choose between options, but the home page lists no pharmacies and posts no 503A/503B classifications. The marketplace claim is structural; the transparency isn't.

Pediatric line is offered without public protocol detail. Compounded GLP-1 in pediatric populations is regulatorily and editorially sensitive; protocol opacity on the public surface is a flag.

Multi-month commitments not exposed on the static surface. Plan selectors for 3/6/12 months appear on the home page but the specific pricing only appears inside the onboarding flow. Patients can't comparison-shop without committing to the funnel.

Featured physicians vs. marketplace pool size. Mochi names four physicians on the home page as featured examples. The actual marketplace pool — total roster, geographic coverage, and average wait time — is not disclosed. The "choose a provider" promise carries different weight at a pool of 50 vs. 500.

Compounded medications are not FDA-approved, and tirzepatide / semaglutide availability is regulation-sensitive (recheck after the FDA's 29 June 2026 comment deadline).

Mochi Health makes the most sense for the patient who wants the lowest all-in compounded-GLP-1 cost with a dietitian included and who values the conceptual idea of provider choice plus pharmacy choice over the deeper transparency a single in-house operator might offer. It fits people who'd rather have a registered dietitian on call than a higher-touch behavioral program, and who are comfortable with a platform that gestures at multi-category breadth without publishing the detail. The Trustpilot sample size is genuinely useful as an independent signal.

Skip it if you want named pharmacies and posted 503A/503B classifications before signing up — Mochi's marketplace transparency is at the structural level, not the in-network-detail level. Skip it if you want footnoted outcome statistics — the home-page numbers are uncited and don't survive our editorial standards. Skip it if a 1.32-out-of-5 BBB customer review rating is a deal-breaker for you. Skip it if you want to avoid a platform with concurrent active manufacturer litigation (both Eli Lilly and Novo Nordisk) and a worker-classification class action. Skip it if you're considering pediatric weight management without specifically interrogating the protocol — the regulatory sensitivity is elevated and the public surface is thin. And skip it if you want the lowest possible cost without a recurring membership fee — Mochi's all-in monthly ($178 semaglutide / $278 tirzepatide after the promo first month) is competitive but not absolutely cheapest in the category.

Our editorial position is to keep head-to-head verdicts in dedicated comparison pages rather than inside any single review. The shape of Mochi's position is clear enough at this level.

Against the other large-volume compounded-DTC operators (Henry Meds), Mochi has a similar Trustpilot footprint, includes a dietitian layer that Henry doesn't advertise, and has a more transparent named-physician home page. Henry undercuts Mochi on annual paid-in-full pricing and has a clean 503A/503B disclosure that Mochi doesn't match. Against the multi-category compounded operators (TeleZenMD), Mochi has a narrower real menu but lower entry pricing and a substantially larger independent-review footprint. Against the branded-only operators (Hims, Ro), Mochi's price floor is much lower but the evidence base is weaker — compounded versus the FDA-approved branded products Hims and Ro now lean on.

The clearest case for Mochi over any of those alternatives is wanting a low all-in compounded GLP-1 cost with provider and pharmacy choice and a dietitian included.

How we reviewed this. Pricing, programs, and process details were pulled directly from Mochi Health's public home page in June 2026. The full price ladder for multi-month memberships sits inside the onboarding flow rather than the static marketing surface and was not entered for this review. Prescriber verification was conducted independently against the public NPI Registry — two of the four featured MDs are individually verifiable with the credentials Mochi describes (Family Medicine plus Obesity Medicine, and Internal Medicine plus FACP). The other two featured physicians remain pending NPI verification at the level required for inclusion in this review. Third-party review platforms: Trustpilot shows 16,207 reviews at 4 stars — a large sample. The Better Business Bureau lists Mochi at a 1.32-out-of-5 customer review rating, per Forbes Health (28 April 2026). Litigation history: Mochi is defendant in three concurrent matters — Eli Lilly and Company v. Mochi Health, Inc., Mochi Medical CA PC, Mochi Medical PA et al. (filed 23 April 2025, N.D. Cal.; motion to dismiss denied 22 April 2026 per Law360); a parallel Novo Nordisk lawsuit on compounded semaglutide; and a California class action on worker misclassification (filed 11 February 2026 in N.D. Cal.). Clinical claims in this review are anchored to peer-reviewed primary trials (STEP 1, STEP 1 extension, SURMOUNT-1) and FDA primary sources; we do not propagate the home-page outcome statistics (10%/6mo, 36 lbs/year, 16%/year, 5-of-6 retention) as evidence — they are uncited and recorded as company-stated marketing only.

Editorial independence. PeptideWellness does not accept payment from telehealth providers, compounding pharmacies, or manufacturers in exchange for coverage, placement, or scoring. We have no commercial relationship with Mochi Health.

Editorial note: Informational only — not medical advice. Compounded medications aren't FDA-approved and don't undergo the same safety, effectiveness, or manufacturing review as branded pharmaceuticals. GLP-1 therapy decisions should be made with a licensed healthcare provider familiar with your medical history. Last reviewed June 2026.